Lapatinib Completed Phase 2 Trials for HER2-positive Refractory Advanced Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02342587Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer